OXURION NV (OXUR.BR)       0.012  0 (0%)

0.012  0 (0%)

BE0003846632 - Common Stock


Fundamental Rating

0

Taking everything into account, OXUR scores 0 out of 10 in our fundamental rating. OXUR was compared to 53 industry peers in the Biotechnology industry. Both the profitability and financial health of OXUR have multiple concerns. OXUR is valued expensive and it does not seem to be growing.

Note: OXUR has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

0

OXUR has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for OXUR.

VS Industry

Valuation

Valuation Rating

0

The Price/Earnings Ratio is negative for OXUR. In the last year negative earnings were reported.

VS Industry

Growth

Growth Rating

1

OXUR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.43%, which is quite good.
OXUR shows a decrease in Revenue. In the last year, the revenue decreased by -8.42%.

The Revenue for OXUR have been decreasing by -30.79% on average. This is quite bad

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 16.43% N/A N/A N/A N/A
Revenue-30.79% -40.37% -8.42% N/A N/A N/A N/A

Health

Health Rating

0

OXUR has a Current Ratio of 0.96. This is a bad value and indicates that OXUR is not financially healthy enough and could expect problems in meeting its short term obligations.
When comparing the Current Ratio of OXUR to the average industry Current Ratio of 2.87, OXUR is less able to pay its short term obligations than its industry peers. 98% of its industry peers have a better Current Ratio.
A Quick Ratio of 0.95 indicates that OXUR may have some problems paying its short term obligations.
When comparing the Quick Ratio of OXUR to the average industry Current Ratio of 2.87, OXUR is less able to pay its short term obligations than its industry peers. 94% of its industry peers have a better Quick Ratio.

Based on the Altman-Z score of -12.88, we must say that OXUR is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 0.04, OXUR is in worse financial state than most of its industry peers. 96% of its industry peers have a better Altman-Z score.
OXUR has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for OXUR.
VS Industry

Quick Ratio (0.95) VS Industry: 6% outperformed.

0.44
19.39

Current Ratio (0.96) VS Industry: 2% outperformed.

0.44
19.39

Altman-Z (-12.88) VS Industry: 4% outperformed.

-36.40
56.77

Dividend

Dividend Rating

0

No dividends for OXUR!.

OXURION NV0.012

EBR:OXUR (3/21/2023, 12:12:01 PM)0 (0%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) N/A N/A Earnings (Next) N/A N/A
Inst Owners N/A Inst Owner Change N/A
Ins Owners N/A Ins Owner Change N/A
Market Cap 7.02M Analysts 40
Price Target 1.27 (10483.33%)

Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y) N/A DP N/A
Div Incr Years N/A Div Non Decr Years N/A
Ex-Date N/A

Surprises & Revisions
EPS beat(2) N/A Avg EPS beat(2) N/A
Min EPS beat(2) N/A Max EPS beat(2) N/A
EPS beat(4) N/A Avg EPS beat(4) N/A
Min EPS beat(4) N/A Max EPS beat(4) N/A
Revenue beat(2) N/A Avg Revenue beat(2) N/A
Min Revenue beat(2) N/A Max Revenue beat(2) N/A
Revenue beat(4) N/A Avg Revenue beat(4) N/A
Min Revenue beat(4) N/A Max Revenue beat(4) N/A
PT rev (1m) 0% PT rev (3m) 0%
EPS NQ rev (1m) N/A EPS NQ rev (3m) N/A
EPS NY rev (1m) N/A EPS NY rev (3m) N/A
Revenue NQ rev (1m) N/A Revenue NQ rev (3m) N/A
Revenue NY rev (1m) N/A Revenue NY rev (3m) N/A

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.65
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM) -0.66 EY N/A
EPS(NY) N/A Fwd EY N/A
FCF(TTM) -0.05 FCFY N/A
OCF(TTM) -0.05 OCFY N/A
SpS 0 BVpS 0
TBVpS 0 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM 50.9%
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y 7.39% GM growth 5Y 70.73%
F-Score 2 Asset Turnover 0.08

Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.68%
Profit Quality N/A
Current Ratio 0.96
Quick Ratio 0.95
Altman-Z -12.88
F-Score 2 WACC 5.85%
ROIC/WACC N/A Cap/Depr(3y) 4.03%
Cap/Depr(5y) 4.78% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 16.43% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 23.81%
EPS Next Y N/A EPS Next 2Y N/A
EPS Next 3Y N/A EPS Next 5Y N/A
Revenue growth 1Y -8.42% Revenue growth 3Y -40.37%
Revenue growth 5Y -30.79% Revenue growth Q2Q -21.92%
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
EBIT growth 1Y 15.48% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year N/A
EBIT Next 3Y N/A EBIT Next 5Y N/A
FCF growth 1Y 4.29% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y 4.02%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the EuroNext

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the EuroNext

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the EuroNext

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the EuroNext